Clinicaltrials.gov identifier:
NCT04030559 (https://clinicaltrials.gov/show/NCT04030559)
High-risk localized prostate cancer
NOTE: This study is no longer recruiting people.
This study will look at how well the PARP Inhibitor niraparib works, when given before a radical prostatectomy, for people with high-risk prostate cancer that has not spread to other parts of the body, and who have a tumor mutation in any of the following genes:BRCA1/2, ATM, CDK12, CHEK1/2 FANCA, FANCD2, FANCL, GEN1, NBN, PALB2, RAD51, RAD51c, and BRIP1.
NOTE: This study is no longer recruiting people.
NOTE: This study is no longer recruiting people.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.